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Abstract
Background: Hope has therapeutic value because it enables people to cope with uncertainty about their future health.
Indeed, hope, or therapeutic optimism (TO), is seen as an essential aspect of the provision and experience of medical
care. The role of TO in clinical research has been briefly discussed, but the concept, and whether it can be transferred
from care to research and from patients to clinicians, has not been fully investigated. The role played by TO in research
emerged during interviews with staff involved in a peripartum trial. This paper unpacks the concept of TO in this setting
and considers the role it may play in the wider delivery of clinical trials.
Methods: The Got-it trial is a UK-based, randomised placebo-controlled trial that investigates the use of sublingual
glyceryl trinitrate (GTN) spray to treat retained placenta. Qualitative data were collected in open-ended interviews with
obstetricians, research and clinical midwives (n =27) involved in trial recruitment. Data were analysed using the method
of constant comparison.
Results: TO influenced staff engagement with Got-it at different points in the trial and in different ways. Prior
knowledge of, and familiarity with, GTN meant that from the outset staff perceived the trial as low risk. TO
facilitated staff involvement in the trial; staff who already understood GTN’s effects were optimistic that it would work,
and staff collaborated because they hoped that the trial would address what they identified as an important clinical
need. TO could fluctuate over the course of the trial, and was sustained or undermined by unofficial observation of
clinical outcomes and speculations about treatment allocation. Thus, TO appeared to be influenced by key situational
factors: prior knowledge and experience, clinical need and observed participant outcomes.
Conclusions: Situational TO plays a role in facilitating staff engagement with clinical research. TO may affect trial
recruitment by enabling staff to sustain the levels of uncertainty, or individual equipoise, necessary to collaborate with
research while also responding to patients’ clinical needs. Staff may benefit from training to deal with fluctuations in TO.
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Background
This paper is based upon data generated in interviews
with healthcare professionals as part of a qualitative
evaluation of a UK peripartum randomised placebo-
controlled trial (RCT), the Got-it trial, which looked at
the use of glyceryl trinitrate (GTN) for the delivery of
retained placenta (see Table 1). The Got-it trial con-
tained an inbuilt pilot phase, and certain recruitment
targets had to be reached for the trial to continue. The
aim of the qualitative research was to evaluate staffs’ and
patients’ experiences of the trial’s recruitment proce-
dures and consent pathway to see if these aspects of trial
delivery could be improved prior to rollout of the main
trial. This evaluation was included because the trial team
were concerned that staff may find recruiting and con-
senting women challenging because the trial was taking
place during the peripartum period, when women were
in a vulnerable situation and required to make a decision
about trial participation quickly. Thus, a significant pro-
portion of the interviews with staff were spent exploring
their broader views about, and understandings of, the
trial, including its role and purpose, in addition to its
organisation and their experiences of recruitment and
consenting individual women. These questions sought to
determine what interviewees thought were the barriers
and facilitators to recruitment and how these might be
overcome or emphasised in the main trial, so that staff
could be best supported to undertake recruitment.
When answering these questions, staff reflected at length
upon their hopes and uncertainties regarding the Got-it
trial. While we had expected that staff would be primar-
ily concerned with the organisational issues associated
with trial recruitment and delivery, as the interviews
progressed it became clear that a sense of optimism
about the trial was critical to staffs’ on-going commit-
ment to, and involvement with, the trial and thus funda-
mental to ensuring recruitment to Got-it. The idea of
therapeutic optimism (TO) in the context of clinical
research has been briefly discussed in the literature, but
the role it might play in the delivery of clinical trials is
poorly defined, as is the concept itself. Using empirical
data collected in interviews with staff, this paper will
expand the concept of TO by looking at the role it plays
for staff recruiting to the Got-it trial.
The role of hope, therapeutic optimism and uncertainty
in clinical research
The phenomenon of hope, expressed as therapeutic
optimism, is an essential aspect of medical care.1 Hope
is described within the medical and bioethics literature
as having therapeutic value because it enables people to
cope with uncertainty about their future health [1, 2].
Hope or TO can be defined as a positive, future-
oriented [1] emotional state, which manifests as a desire
for a particular healthcare outcome [3]. Martin [3]
contends that hope also involves cognitive elements, in-
sofar as it plays a role in framing individuals’ imaginative
engagement with, and understanding and use of, infor-
mation about desired outcomes. These features, he
argues, may result in biased decision-making about
medical treatment or research participation and thus
render patients “vulnerable to exploitation” ([3], p. 52).
For example, individuals’ desire for a cure can bias their
perceptions of research outcomes and influence their inter-
pretation of information about research participation [2, 4].
Research participation is frequently described as moti-
vated by a number of cognitive biases or “mis”understand-
ings that help individuals to deal with the uncertainty that
lies at the heart of clinical research [5]. In a trial context,
in addition to therapeutic optimism (TO), namely, hoping
that one will benefit from trial participation [3, 6], these
include therapeutic misconception (TM), or conceiving of
research as needs-driven rather than hypothesis-driven,
which is associated with holding the belief that the care
offered in the trial is driven by personal need not scientific
Table 1 The Got-it trial
“The Got-it trial is a randomised placebo controlled double blind pragmatic
UK-wide RCT involving women who have a retained placenta (RP)
recruited from delivery wards in UK maternity hospitals. RP is a major cause
of postpartum haemorrhage and affects around 2 % of vaginal deliveries
in the UK. It is diagnosed when the placenta is not delivered within
30 minutes following active management or 60 minutes after physiological
followed by active management of the third stage of labour after delivery
of the baby [26]. Although some placentas can still be delivered vaginally
after a RP is diagnosed, the chance of this happening is low and decreases
the longer the placenta remains in situ. The definitive management of RP
is, therefore, manual removal of the placenta which is a surgical procedure
requiring trained personnel and an operating theatre. The aim of the
Got-it trial is to determine whether use of glyceryl trinitrate (GTN) spray, as
compared to a placebo, can facilitate delivery of the placenta without
having to undertake manual or surgical delivery in theatre. GTN is a drug
that was originally developed for the prevention and relief of angina
attacks. Its side-effects include headache, dizziness, flushing/feeling hot, a
drop in blood pressure or a rise in pulse. In the clinical context of RP, it
could also affect blood loss due to its primary mode of action as a muscle
relaxant. For the trial’s inclusion and exclusion criteria see Lawton et al. [17].
The trial comprises an internal pilot followed by a substantive RCT. The
pilot commenced in October 2014 and involved eight sites that entered
the pilot in a staggered way. During the pilot, once a diagnosis of RP had
been made, a delegated and trained member of the clinical or research
team approached potential recruits. These women were given written
information in the form of a one page summary leaflet accompanied by a
detailed participant information sheet. Women were also given a verbal
explanation of the trial that covered all the elements in the participant
information sheet and consent form. Women who gave their consent
were randomized to receive GTN or a placebo spray, which they
self-administered under their tongue (two puffs). The placebo spray
was designed to be identical in taste and appearance to GTN so neither
participants nor staff could determine the outcome of randomization.
Women who did not deliver their placentas within 15 minutes were taken
to theatre for manual removal of the placenta under regional or general
anaesthesia, with the method of anaesthetic being determined by the
clinical team and being dependent on the urgency of need for placental
delivery.”
Excerpts from Lawton et al. [17]
Hallowell et al. Trials  (2016) 17:267 Page 2 of 13
curiosity [7–10], and therapeutic misestimation (TME), or
consistently (mis)estimating or (mis)calculating the risks
and benefits of participation in one’s favour [4, 5]. It has
been argued that all of these may have ethical conse-
quences because they can influence participants’ decision-
making and, therefore, their ability to give fully informed
consent [2–4, 6, 8, 11–13].
Although TO, TM, and TME have been observed fre-
quently in research participants [2, 9, 12, 13], the extent
to which healthcare professionals subscribe to these
biases is less well documented. Research suggests that
clinical staff may be subject to TM [14], and TME and
TO have been observed in staff involved in the delivery
of phase 1 oncology trials [4]. Few researchers have
looked at whether and in what ways TO influences staff
outside of phase 1 trials, although a number of authors
have suggested that researchers may capitalise on poten-
tial participants’ TO in their efforts to increase trial
recruitment [3, 4, 6, 15].
Characterising therapeutic optimism in clinical research
The literature suggests that hope and uncertainty exist
in a complex relationship within clinical research.
Clinical trials take place because there is uncertainty
about the efficacy and utility of an intervention, but
while uncertainty (or clinical equipoise) is a necessary
feature of ethical research [16], researchers and research
participants may find this unsettling and attempt to
counterbalance their feelings of uncertainty with hope,
and this may have ethical repercussions [4, 6].
The degree to which TO affects the ethicality of
research has been discussed by Horng and Grady [5],
who suggest that TO, or hope, is unavoidable when
participating in clinical research. In contrast to TM or
TME, they argue that TO — “personal optimism” or
hoping for the best — is not ethically problematic,
should be tolerated and even “actively preserved” ([5], p.
16), at least until it results in “misunderstanding” the
risks and benefits of trial participation. However, Horng
and Grady [5] are unclear about how misunderstanding
can be distinguished from TO, and this, Jansen [6]
argues, is because they do not specify the nature of TO,
and also view it as a uni-dimensional phenomenon.
In her 2011 paper, Jansen [6] argues that what the
literature describes as TO is, in fact, two contrasting
phenomena. The first, dispositional optimism, is an indi-
vidual character trait or disposition, which manifests as
a generalised positive outlook on the world — always
hoping for the best. The second, situational optimism, is
focussed upon “particular events or activities” — hoping
for the best in this situation. Situational optimism can
be seen as an emotional response or reaction to a
particular aspect of the environment and, because it is
influenced by external factors, may be realistic or
unrealistic. Dispositional optimism, on the other hand, is
a way of interacting with the world, which, because it is
internally generated, cannot be categorised as realistic or
unrealistic. Jansen argues that these different types of
optimism have differing ethical implications for clinical
trials. For example, she suggests that research participants
who are by nature optimistic, i.e. who exhibit dispositional
optimism, are more likely to give valid informed consent
than those whose optimism is influenced by external
factors and who have unrealistic expectations about a
particular outcome, i.e. display unrealistic situational
optimism. The latter, she contends, are more vulnerable
to external manipulation and prone to biased decision-
making. Thus, for Jansen, dispositional optimism is seen
as much less ethically problematic than situational opti-
mism, which can be influenced by others and, in the case
of unrealistic situational optimism, may invalidate in-
formed consent by undermining individuals’ autonomy.
One of the problems with Jansen’s analysis of TO is
that it does not specify how the different dimensions of
TO are expressed, interact and potentially influence be-
haviour. But while her analysis may be less well defined
than one might like, arguably in distinguishing different
types of TO and examining their ethical significance, Jansen
makes an important observation - namely, not all manifes-
tations of TO are equal when it comes to their ethical im-
plications. That said, following Jansen, it can be argued that
if her conception of situational TO is to be used more
widely, then we need to determine how situational TO be-
comes manifest and is sustained in practice.
To date, most of the discussion about TO in the
context of clinical trials has dealt with research
participants — focussing on how TO may bias their
decision-making and invalidate their consent or how
participants’ TO can be manipulated by researchers
during the recruitment process. However, as noted
above, it is not only patients or their proxies who
may be optimistic about research interventions. As
both Miller [4] and Martin [3] argue, clinical
researchers may be optimistic about the outcomes of
a clinical trial; they may hope for beneficial outcomes
for their patients and this may influence their
approach to research. Using staff accounts of their
involvement in a peripartum RCT, this paper looks at
how TO may influence staff participation in research.
The analysis presented here suggests that, in certain
circumstances, hope, expressed as situational therapeutic
optimism, facilitates staff engagement with research and,
therefore, may influence trial recruitment.
Methods
Study aims
The aim of this qualitative study was to explore staff ’s
and women’s experiences of, and views about, the
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information and consent pathway used in the pilot phase
of the Got-it study (see Table 1). Full details of the main
trial can be found on the International Standard
Randomised Controlled Trials Number (ISRCTN)
website.2 The analysis reported below focuses on staff
members’ views and experiences of recruiting to the
trial; data collected in interviews with women have been
reported elsewhere [17].
Study setting
Before describing our study, it is important to provide
some context for the interpretation of our data. First,
with regard to the trial itself, it must be noted that
the study drug (sublingual glyceryl trinitrate spray,
GTN) used in Got-it has a very short half-life
(Table 1). This means that the primary outcome,
namely, the delivery of the placenta, will occur within
15 minutes of administration of the trial intervention,
thus enabling recruiting staff to directly observe the
outcome of drug administration in their patients. In
other words, in contrast to many trials where the pri-
mary endpoint may be spatially and temporally re-
moved from the recruitment site, the link between
intervention and outcome in Got-it is fairly tight, and
thus, while the trial is blinded to staff (and research
participants), the outcome for individual women is
“directly” observable by those involved in trial
recruitment.
Second, we feel it is important to provide some
details of the clinical context in which the Got-it trial
takes place. Because continuity of care is emphasised
in birthing centres and labour wards, midwives (and
doctors) often develop close (and intimate) relation-
ships with the women in their care. If a woman has
to go to theatre for a manual removal of the placenta,
many of the important jobs that midwives have to do
in the immediate postpartum period (i.e. initiating
mother-baby bonding, skin-to-skin contact with baby
and breast-feeding initiation) will be delayed, and in
some cases the much valued continuity of care will
be interrupted. Moreover, it is generally acknowledged
that, while a manual removal of the placenta normally
takes place under regional anaesthesia with the
woman awake, it is an unpleasant and invasive pro-
cedure, particularly if it follows a labour that has
involved the minimum of intervention and pain relief.
Thus, arguably, birthing centre and labour ward staff
have a vested interest in the Got-it intervention
working, because if GTN works, it means that
midwives can maintain their relationship with women,
deliver their postnatal care more efficiently and
potentially move the woman on to the postnatal ward
more quickly.
Ethical approval
REC approval was given by the Newcastle and North
Tyneside 2 Research Ethics Committee (13/NE/0339).
The study was also approved by the Medicines and
Healthcare Products Regulatory Agency (MHRA),
Eudract Number: 2013-003810-42. Written informed
consent was obtained from participants for publication
of their individual details and accompanying quotes in
this manuscript. The consent forms are held by the au-
thors and are available for review by the Editor-in-Chief.
Recruitment
Staff members involved in recruitment to the pilot phase
of the trial were sent invitation packs containing opt-in
forms, information leaflets and consent forms. Staff were
recruited from all of the eight pilot sites. Individual staff
members were approached following their involvement in
the recruitment of individual women, and we continued
recruiting across the pilot sites until we had a sample that
included staff with varying degrees of exposure to the trial.
Recruitment continued until data saturation was achieved,
that is, until no new themes were identified in new data.
To safeguard confidentiality, all participants were allo-
cated pseudonyms, and these are used below.
Data collection and analysis
With one exception, data were collected during tele-
phone interviews (40–90 minutes duration) conducted
between November 2014 and May 2015. The interview
topic guide was based upon the research questions and
the literature, and included questions about: experiences
of trial delivery — particularly recruitment and taking
consent — perceptions and understanding of the trial
design and the intervention (GTN) and general views of
participation in research and its impact on the health-
care professional-patient relationship. The study was
informed by the principles of grounded theory [18] and
involved simultaneous data collection and analysis. All
interviews were audio-recorded and transcribed. A
conceptual framework for indexing and analysing data
was developed using the method of constant comparison
[19]; this enabled the identification of recurrent themes
between and within interviews. Transcripts were read
and coded by NH and JL, who discussed the emerging
findings. NVivo9 (QSR International) software was used
to facilitate data coding and retrieval.
Results
Interview participants
Of the 37 staff members who replied, 27 (73 %) were
interviewed, including clinical midwives, research mid-
wives and obstetricians (consultants, registrars, specialist
trainees) (Table 2). As Table 2 indicates, the final sample
had varying amounts of clinical and research experience.
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Staff were purposively sampled to reflect different trial
experiences. Some sites had come on board at the
start of the pilot and had been recruiting throughout
the 7-month period, whereas others had only gone
live during the last 2 months of the pilot phase.
Length of time recruiting to the trial in the site plus
the size of site meant that recruitment rates across
the sites varied, and this was reflected in our sample,
which included staff from sites where between 2–14
(mean 7.5) women had been recruited during the
period when staff were interviewed. Some staff were
interviewed relatively late in the pilot phase at their
site, allowing them opportunity to reflect back on a
range of trial experiences, whereas others were inter-
viewed soon after the trial had gone live at their site
and thus had less exposure to trial outcomes. Be-
tween 1–6 (mode 3) staff members were interviewed
from each site.
When reflecting upon their experiences of trial
recruitment, staff talked about their uncertainties and
hopes for the trial. We will begin by describing the
staffs’ uncertainty about the trial and then show how
this was counterbalanced by optimism concerning
trial outcomes. Finally, we present data that describe
how levels of TO were sustained during the trial.
Accounting for uncertainty: initial perceptions of trial design
Research midwife O: See the big thing really for us has
been the hospital staff being on board…They’ve been
really really good. They’ve been watching out for
patients so even when we’re not physically here they’re
actually, you know, they’re helping us with recruitment.
… ‘cause without them on board we’d not get anywhere
with it.
Because involving clinical staff in research, particularly
those who work in highly pressurised environments, is not
always straightforward, as Research midwife O commen-
ted, our interviewees were keen to reflect upon why they
and their colleagues had decided to become involved in
the Got-it trial. Their accounts revealed the existence of
various degrees of uncertainty at both personal and local
levels, which many described as influencing their engage-
ment with the trial. Dr D, who had positive experiences of
using the study drug in the past, still saw uncertainty
about the trial outcomes as providing a rationale for their
involvement with the research.
Dr D: …it’s plausible that it might work. I’ve seen
GTN used in other emergency situations in uterine
inversion. We couldn’t get the uterus back in. We used
GTN to relax the uterus. So I can see the physiology of
why it’d work. I don’t know if it will though (laughs).
I suppose that’s why we’re doing the study.
Others, in contrast, expressed more scepticism about
the use of GTN in this setting. As Dr E said: “if I’m
honest, I don’t think it will [work]. I’m really intrigued
and I’d love it if it did…But if I was gonna be a betting
person, [I] would say that I think it’s not gonna show, it
won’t…”.
There was evidence of scepticism and uncertainty
coexisting at an individual or local (site) level without
this having a deleterious effect upon trial delivery. Dr H,
for example, reflected that even though the staff at their
site were sceptical about trial outcomes, this did not
necessarily put them off recruitment: “…the majority of
the staff who are a little sceptical are still suitably
opened minded that there’s still an uncertainty, that
they’re willing to give it a go.”
However, only a small number of staff described
themselves (or were described) as sceptical about the
study. The majority of our interviewees said that ini-
tially, at least, they remained uncertain about trial
outcomes.
Dr A: I have given GTN to try and relax the cervix,
whether it’s that mechanism… I don’t know for sure so
I believe there is some effect with muscle and things so
I can see that, you know, potentially it will, it could
have an effect and therefore, I definitely think it’s
worth trying. But I don’t think we know.
This latter group talked positively about Got-it. Some
praised the trial’s scientific rationale, like Dr J:
Table 2 Participant characteristics
N = 27 Percent
Obstetricians 10 37
Clinical midwives 6 22
Research midwives 11 41
Education
Professional qualifications 1 4
Degree 26 96
Higher degree 5 19
Time in current post (years)
0-2 years 9 41
2.5-5years 13 48
5.5-10 years 2 7
> 10 years 3 11
No previous research experience
Research midwives 0 0
Obstetricians 4 15
Midwives 2 7
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Yeah, it’s definitely a good, good idea, and the thinking
about behind it is fairly reasonable as well, in terms of
using GTN to relax the uterus to deliver the placenta.
Yeah, so I think it’s a really good trial.
Others in this group extolled the need for, and thus
the potential benefits of, the intervention.
Clinical midwife C: But to be honest, I think the only
incentive that I, or any midwife, would need is the
possibility that it might work. And that you might be
avoiding a trip to theatre — no one wants a trip to
theatre, no one: the midwife doesn’t want a trip to
theatre, the doctor doesn’t and the woman certainly
doesn’t. So we’re all working towards the same
ultimate goal, to get the placenta out without going to
theatre. So for me, that’s all the incentive I need, I
would do anything to get that placenta out without
going to theatre.
Many interviewees dealt with their uncertainty regard-
ing the use of GTN in this clinical setting by adopting a
hopeful attitude towards the trial. The interviews revealed
that staffs’ TO about Got-it was fuelled by a number of
situational factors. The first, as the next section demon-
strates, was staffs’ familiarity with the study drug: GTN.
Familiarity breeds therapeutic optimism: perceptions of
the study drug
Many staff members commented that their prior know-
ledge about the way GTN works in the body made them
feel more confident about becoming involved with this
trial, because they felt that they understood the rationale
underlying the study hypothesis.
Dr E: I think it helps staff, or it brings up more
questions I guess, ‘cause staff are thinking they know
what the drug is. So they’re instantly thinking, well
GTN does that. Ooh we’re doing the opposite to what
we normally do with oxytocin we make everything
contract, we’re getting everything to relax… It just
makes it more accessible I guess, in the sense that
people recognise the drug, so instantly can start to
hypothesise what the rationale is for the trial, without
reading anything.
The fact that most staff had used GTN before and
were aware of its effects and side effects gave them a
feeling of security when recruiting participants and
administering the intervention. As Dr F said: “The image
I have of it is that it’s not particularly dangerous …I
don’t see it as being a dangerous drug.” Indeed, most clin-
ical staff said they regarded GTN as a safe intervention,
even in this novel setting, a view that was influenced by
using the drug in more familiar but notably different
clinical contexts, such as for the treatment of angina.
Staff also described their previous experiences of
using GTN as making them feel “more comfortable”
using it in the trial (Dr C) and more confident about
explaining drug-associated risks and benefits to po-
tential participants.
Dr H: It’s a lot easier actually to talk about a drug
that you’ve got quite a lot of knowledge and experience
and has been around for a long time than something
new that all you’ve got is theoretical knowledge that
you’ve been told.
Familiarity with GTN, therefore, allowed staff to off-
set many of their uncertainties about the trial inter-
vention. While they did not know what the outcome
of the trial would be, the fact that they had used
GTN before to beneficial effect influenced their views
of the trial and their role in trial delivery. Previous
experiences of using GTN were described as enabling
staff to confidently weight the risks and benefits of
study participation and allowing them to reach the
conclusion that Got-it was a safe trial, with less
uncertainty and fewer unknowns than trials which involve
novel and untested treatments. Prior knowledge can thus
be seen as promoting staff buy-in from the outset; because
staff were familiar with GTN and perceived it as a rela-
tively risk-free intervention, they were optimistic about
the Got-it trial and happy to become involved in re-
cruitment. However, familiarity with GTN was not
the only situational factor that was reported as influ-
encing optimism about Got-it. As the next section
demonstrates, TO was also motivated by the fact that
the trial potentially addresses what all staff identified
as a pressing clinical need.
Constructing therapeutic optimism: perceptions of
clinical need
All interviewees talked about the impact GTN could
have on peripartum care if the trial were to be success-
ful, and these potential benefits clearly drove optimistic
views of the trial.
Research midwife M: I think the benefits of it
[GTN], if it did work, would save such a lot of
time, inconvenience, pain for the woman, distress
and separation. And there are so many benefits I
think the midwives are keen to do it. The way they
say, ‘if it does that, and prevents all that, how good
this will be’. And especially for the future, if it does
work, being able to use in birth centres and
community settings. Yeah the benefits of it will be
really good if it did just have an effect.
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The fact that trial participation may prevent a woman
from having to go to theatre to undergo what some de-
scribed as a brutal and “degrading” (Clinical midwife N)
procedure and be parted from their baby was described
as the ultimate incentive for recruitment.
Research midwife G: I think if it [GTN] can prove to
work, then fantastic. It’s definitely worthwhile trying it
and seeing, you know, where it comes from. Cause I
think anything that can stop the women to have — a
manual removal’s just awful. And I think when you’ve
seen a few, it’s so barbaric you feel like you’re on a
farm. Poor woman, watching them go through that. So
I think anything that can be shown to stop that having
to happen, then fantastic.
Others noted that if GTN is shown to work in this
context, then it would not only benefit women and their
family, but also obstetrics more widely, because it would
decrease staff workload and result in better targeting of
clinical resources.
Dr I: From the doctor’s point of view, you know, it’s
obviously better for the woman as well, less risk and
less medicalisation the day after. But it’s also less
work. You can concentrate, focus on women who are in
labour, or who may be sick or you know, other women.
Got-it was seen as an easy trial to deliver, not only
because the intervention is relatively straightforward to
administer [17], but also because the staff identified a
pressing clinical need for a drug that would enable
women to deliver their placenta safely and simply. Clin-
ical midwife N expressed her hope that the trial would
demonstrate the efficacy of the intervention.
Clinical midwife N: I hope it does… if it works it will
be amazing because it will reduce these women going
to theatre for such an invasive procedure …if it works
it will be amazing because it will keep families
together.
Thus, TO was motivated by staff perceptions of
clinical need, which in turn provoked a commitment to
recruit women to the trial.
Research midwife H: I think, with this trial in particular,
because it is to do with retained placentas. And the
midwife, you know, often does feel bad when they have to
go to theatre. And you do question, could I have done
anything different that would have changed the outcome.
So by having some other option, rather than theatre,
I think lots of midwives feel, you know, we really want
to try this.
However, as the next section demonstrates, TO did
not remain constant throughout this trial. Indeed, there
was evidence that for some staff members, and in some
sites, TO was constantly shifting, and these fluctuations
were described as potentially impacting on recruitment
rates as the staff concerned engaged with or disengaged
from the trial.
Maintaining therapeutic optimism and sustaining trial
recruitment
Therapeutic optimism is all about outcomes, not only
hoped-for or desired outcomes, but actual eventualities.
The staff interpreted outcomes for women in the trial —
the delivery of a placenta in the delivery room following
administration of the study drug or the manual removal
of a placenta in theatre — as either the realisation or
eradication of their hopes, respectively. There was
evidence that staff were informally monitoring trial
outcomes and that this influenced levels of TO. For
example, Dr I reflected that it was a combination of their
prior knowledge of GTN and witnessing GTN actually
“working” in the trial that had increased their optimism
about Got-it and led them to conclude that “it will show
something.”
I: Is it working so far?
Dr I: Yes I think so. And the staff think so. Because
they think they can smell the drug. But obviously that’s
just in their head. The Band 6 midwives have said as
soon as the puffs are given it seems to come out. I
think one midwife’s been involved in two cases, well
we’ve only — done six or seven, so you know. But I
think it will show something…And I think from what
I’ve seen it seems to work. …I think, the way the drug
works, it should — I’m hoping it’ll work. And I think it
will. That’s just because of the drug characteristics and
a little bit of what I’ve seen.
Increasing levels of TO were seen to affect staff
behaviour. Research staff described how the delivery of a
placenta following randomisation had resulted in in-
creased levels of optimism about Got-it at their site,
which resulted in greater numbers of women recruited
in the immediate aftermath.
I: Do you feel that helps once there’s a success?
Dr H: When we had that one everybody was really
excited and I think fairly shortly after that we
randomised quite a lot more people.
But not all randomisations result in successful out-
comes, and staff went to great lengths to ensure levels of
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TO were maintained despite witnessing negative out-
comes for women. For example, in some cases when
women had gone to theatre for a manual removal after ad-
ministration of the intervention, it was suggested that the
outcome was nearly successful, because they had not re-
quired a “proper manual removal”, and it was speculated
that, in these cases, women had nonetheless received the
study drug.
Research midwife A: In [site] there’s been seven
[randomisations]. So far all our ladies have
unfortunately gone to theatre. However, I think about
three of them the placenta has been sitting in the
vagina when they’ve got there. So, we would, well
I — would assume that they possibly have had the
drug rather than the placebo as opposed to the ladies
that have gone on to need a proper manual removal,
it suggests that they’ve possibly had the placebo.
It was frequently observed that if a woman had needed
surgical intervention, then it was more likely that she
had been allocated to placebo. As Clinical midwife N
commented: “I think she got placebo because it didn’t
come out. I do think that she did get a placebo but we
don’t know do we, so I don’t know.”
While successful outcomes and speculating about trial
allocation may enable staff to maintain TO, if a centre
witnessed a large run of manual removals following
administration of the intervention, this could result in
declining levels of TO.
Research midwife I: I think we may have six or seven
[recruits], and then it’s only one that’s been successful.
…I’m not sure why, I don’t know the reason. They
might all be placebos they’re getting. Or it may not
work. It’s hard to say, isn’t it? But, we just feel a bit
disheartened really. And it kind of drops the morale
with the staff a little bit as well, when you just keep
getting a bit of a negative result with it. And we think
that staff might start to think, is there any point in
doing the Got It trial. It’s not going to work … I just
feel it would be nice if we got some positive results to
kind of encourage staff a little bit more.
A number of the research staff across the pilot
sites said they worried that a lack of successful out-
comes or an increasing number of adverse events in
their site could negatively affect trial recruitment
rates, as staff became less optimistic and more scep-
tical about trial outcomes. Although none of the staff
interviewed at Site C reported engaging in selective
recruitment practices, they were reported as adopting
a more precautionary stance with regard to recruit-
ment after a number of postpartum haemorrhages
(PPH) occurred following administration of the study
drug.
Research midwife G: ‘Cause we’ve had quite a few
PPHs. And obviously, we don’t know if it’s linked or
not. But it’s put a lot of the midwives, and doctors
[off] …when they talk, quite candidly, then they will be
honest and just say, well it does put them off, because
they don’t want to go in — a woman that’s quite nice
and stable, and then they seem to take two puffs of
this and they suddenly start bleeding and it becomes
an emergency situation, rather than a calm situation
that needs dealing with. It seems that, a few of them
have had that repeated experience and it’s just really
put them off.
However, the research staff also suggested that
declining TO (and recruitment rates) and a negative
shift in levels of uncertainty at an individual/site level
could be reversed by a run of successful outcomes,
which, as they speculated, would “instil faith” in the
trial and boost TO, and thus, stimulate recruitment.
As Research midwife O said: “…we’ve had now four
who haven’t worked, one that has. So if they just give
me a few more that work I think to instil faith.”
Such comments highlight the complex relationship
that exists between TO and uncertainty for staff.
Research staff, in particular, acknowledged that TO or
“faith” in the trial, was important for individual staff
members to sustain the level of uncertainty, which they
regard as necessary to continue to recruit women to the
trial. Witnessing successful trial outcomes can be seen
as important in this respect, because they appeared to
directly affect staff perceptions of the trial, in the sense
that a successful delivery was described as leading to
increased optimism about the trial, which results in a
motivation to recruit. A lack of success, particularly a
run of visits to theatre or adverse events (Site C), was
reported as leading to declining levels of TO and poten-
tially negatively affecting levels of uncertainty, which
resulted in staff emotionally and (potentially) physically
disengaging from the trial, as they began to perceive the
research as conflicting with their duties of care.
In summary, TO was reported as a dynamic
phenomenon, as fluctuating at both an individual and
site level during the pilot phase of Got-it. As noted
above, these fluctuations in TO appear to be directly
influenced by situational factors — recruiting staff
members witnessing particular trial outcomes — and
can be seen as important, because if levels of TO
decline too far and too widely within a site, then, as
discussed in the next section, staff may shift out of
individual equipoise and trial recruitment may be
negatively impacted.
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Discussion
This paper has reported the experiences of research and
clinical staff involved in the delivery of a peripartum
RCT in the UK: the Got-it trial. The data suggest that
recruitment to Got-it could be indirectly influenced by
shifting levels of TO about the trial held by staff
members. It was observed that, while there was evidence
of uncertainty about trial outcomes at a personal level,
this uncertainty was balanced by the hope that the inter-
vention might work and this TO motivated staff engage-
ment with the trial. TO, in this instance, appeared to be
influenced by a number of situational factors, i.e. staff
members’ familiarity with the study drug and percep-
tions of clinical need, and was reinforced or undermined
by witnessing the outcome of administering the inter-
vention to their patients.
The interviews suggest staff were informally monitoring
trial outcomes in individual cases to see whether the
intervention was working or not, and this resulted in
fluctuations in levels of TO. Indeed, there was evidence
that staff not only continuously scrutinised individual out-
comes at their site, but also re-framed negative outcomes
to reinforce pre-existing levels of TO. This monitoring
and reframing of trial outcomes can be seen as important,
because it was observed that declining levels of TO have a
negative impact on levels of uncertainty, resulting in
greater scepticism, which in turn may negatively affect re-
cruitment rates. Following a brief discussion of our data in
the light of Jansens’s analysis of TO [6], we will consider
the wider implications of TO for trial delivery, specifically,
its relationship with individual equipoise and some of the
ethical and practical implications of our analysis.
The nature of TO in the Got-it trial
Jansen [6] argues that in order to (ethically) accom-
modate TO within research, we need to distinguish
dispositional and situational optimism. While we did
not investigate dispositional optimism in this study,
our analysis of staff experiences of trial delivery sug-
gests that their views of the trial and commitment to
recruitment were, at least in part, underpinned by
realistic situational TO. Our data suggest that staff ’s
situational TO involved a complex convergence of
personal (knowledge and perceptions) and external
(trial outcomes) factors that were particular to this
situation.
First, staffs’ prior knowledge of the study drug and
previous experiences of using it in clinical situations
meant that they felt they could realistically appraise the
trial hypothesis; they could see how GTN might plaus-
ibly work in this setting. Staffs’ familiarity with the trial
intervention meant that, from the outset, they saw Got-
it as a feasible, low-risk study, primarily because they
perceived GTN as a tried and trusted intervention and
also one which is easy for women to self-administer [17].
These staff did not just blindly hope for the best, like the
parents entering their children into high-risk early-stage
trials described by Woods and colleagues [2] or the staff
[4] and patients [4, 13] involved in phase 1 trials. Rather,
when considering whether to become involved with
Got-it, they drew upon their pre-existing stock of know-
ledge of and experience with GTN, and this knowledge
can be seen as underpinning their optimism about the
trial outcomes.
Second, the data suggest that TO is grounded upon
staffs’ perceptions of clinical need. The staff described
Got-it as potentially addressing an unmet clinical need
in their patients, and, therefore, they wanted the trial to
work. In this sense, the staff ’s views of Got-it are similar
to those recounted by Miller, who argues that the
optimism displayed by clinician-researchers involved in
phase 1 trials serves as a form of affect management
when no other therapeutic options are available and the
clinical need is perceived as high [4]. The difference be-
tween the staff we interviewed and those described by
Miller is that the former appeared to be realistic about
potential trial outcomes, not least because TO was
grounded in their knowledge of the study drug and on-
going observations of trial outcomes, whereas the TO
expressed by clinicians in phase 1 trials often involves
TME and has been seen as unrealistic [4].
Third, the reports of fluctuating TO at individual and
site levels confirm that the type of optimism observed in
the Got-it trial is situational rather than dispositional
[6]. TO in Got-it was influenced by witnessing the inter-
vention apparently working or failing in individual cases,
which often resulted in increased or decreased levels of
TO. The fact that outcomes for women were reported as
being so influential was not unexpected, as the effects of
medical outcomes on levels of TO are frequently noted
in clinical contexts, where it is observed that patients’
positive responses to treatment reinforce TO [1].
Finally, it can be argued that the TO displayed in staff
accounts is realistic. Not only did their prior knowledge
about GTN enable staff to make informed judgements
about trial design, but also they described themselves
and others as constantly reassessing their perceptions on
the basis of their trial experiences. Thus, TO about the
Got-it trial was explicitly grounded in staffs’ real experi-
ences of trial delivery, not hypothetical speculations
about its potential therapeutic benefits [2, 4]. Arguably,
it is this balancing of hope and scepticism about the
trial, in the context of their former and current experi-
ences, that affects staff engagement with the Got-it trial
and, ultimately, influences and affects recruitment
practices. In the following section we will discuss how
TO interacts with uncertainty, or individual equipoise,
to potentially affect trial recruitment.
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The relationship between TO and individual equipoise:
balancing hope and uncertainty
Before we discuss the role played by TO in counterbal-
ancing scepticism about trial outcomes to sustain uncer-
tainty, or individual equipoise, we need to distinguish
different types of equipoise. Freedman argues that clin-
ical rather than theoretical equipoise is needed if re-
search is to be regarded as ethical [16]: “Clinical
equipoise is defined as present or imminent controversy
within the clinical community over the preferred
treatment” ([16] p.141). He suggests that clinical equi-
poise is important from an ethical point of view, because
it does not require individual researchers to be in a per-
sonal state of uncertainty in order to become involved in
research.
Clinical equipoise is knowledge3 based, it involves
balancing the objective evidence for and against different
interventions and requires acknowledgment within the
expert clinical community that there is sufficient uncer-
tainty about which treatment should be used. In other
words, clinical equipoise rests on a lack of consensus, or
disagreement, within the expert clinical community
about preferred treatment [16]. In contrast, when re-
searchers describe themselves, or their local community,
as being in equipoise what they are often referring to is
a phenomenological state of uncertainty. Thus, individ-
ual and local [20] equipoise is not (only) based on the
weighing of objective probabilities or scientific facts and/
or an awareness of clinical equipoise, but also involves
subjective perceptions of certainty and uncertainty.
Individual equipoise can be seen as equally as important
as clinical equipoise for some researchers because,
arguably, it is their uncertainty about research outcomes
which enables them to engage in research without
feeling that they are compromising their clinical obliga-
tions [20, 21].
Individual equipoise may fluctuate throughout a trial,
as individuals or the local community (e.g. trial site)
begin to perceive trial outcomes as becoming more or
less certain, and begin to favour one trial arm over
another as a result [20, 21]. Once researchers, either at a
personal or group level, believe that a particular trial
outcome will or will not occur, they can be said to lack
equipoise, and this can undermine the ethical nature of
the trial if it influences the recruitment process [20, 22].
Indeed, in a recent study of a number of clinical trials
that were experiencing recruitment difficulties, Donovan
and colleagues report that a lack of individual equipoise
regarding particular types of patients resulted in
selective recruitment practices on the part of individual
doctors, which biassed ascertainment in some of the
trials they observed [23].
The impact of shifting equipoise on staffs’ intentions
to recruit to trials may be explained by the fact that staff
find certainty and uncertainty in clinical trials difficult to
manage. Donovan et al. [23] and Snowdon [20] report
the staff they studied as moving in and out of equipoise
during the lifetime of a trial. In these studies, staff dealt
with uncertainty by embracing it or dismissing it and
opting for greater certainty displayed by personal [23] or
site [20] preferences. In our study, interviewees’ involve-
ment in recruitment appeared to have had less to do
with levels of individual equipoise, or individual or group
beliefs about the efficacy of the trial, than their hopes
that the trial intervention would work and their patients
would not have to undergo a surgical procedure. Indeed,
it can be argued that the relationship between levels of
TO and individual equipoise in the Got-it trial was cru-
cial in determining staffs’ commitment to recruitment.
Our data suggest that the relationship between TO
and uncertainty about trial outcomes, or individual
equipoise, is complex. As noted above, individual equi-
poise can be seen as a dynamic phenomenon in which
perceptions of certainty and uncertainty constantly shift
during the lifetime of a trial [20]. We suggest that the
point at which fluctuating levels of certainty-uncertainty
compromise individuals’ obligations of care, and conse-
quently threaten trial recruitment, is dependent on
individuals’ TO. In this study TO, or a desire for the trial
intervention to work, was frequently expressed by staff
involved in trial delivery and, arguably, this TO was es-
sential for sustaining levels of equipoise in staff members
who had repeatedly witnessed negative trial outcomes.
This was particularly evident in the sites where growing
scepticism about the trial was observed amongst staff
members; the research staff in these sites worried about
staff ’s disengagement with the trial, observing that staff
need to maintain a certain degree of uncertainty about
trial outcomes, i.e. to be in equipoise, to motivate them
to keep recruiting in the face of seemingly negative
outcomes. In other words, we would argue that TO was
essential to recruitment in the Got-it study because it
counterbalanced negative shifts in equipoise and thus
allowed staff to retain the degree of uncertainty that they
needed to continue recruiting to the trial.
This study suggests that TO and individual equipoise
coexist in a finely balanced relationship within trials that
permit on-going monitoring of individual outcomes. TO,
like individual equipoise, is a dynamic phenomenon,
which fluctuates throughout these trials and is context-
ually determined by individuals’ trial experiences. Thus,
witnessing unsuccessful trial outcomes or adverse events
may lead to declining levels of TO and disturbances in
equipoise. If levels of TO should become too low, then
individuals may no longer be able to sustain individual
equipoise and, as a consequence, may disengage from
the trial both emotionally and physically, and this
could impact trial recruitment. Evidence of successful
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outcomes, on the other hand, maintains levels of TO
in both individuals and study sites, which promotes
engagement with the trial and sustains the level of
uncertainty, or individual equipoise, that is deemed
necessary for staff members to deliver the trial.
Of course, one thing we have not addressed is what
might happen to trial recruitment if, in the light of their
informal monitoring of trial outcomes, recruiting staff
become unrealistically or over-optimistic about a trial
intervention. While this was not an issue in Got-it, we
can speculate that if staff only witness positive outcomes
and/or are not exposed to negative outcomes or adverse
events, then this may affect their levels of TO and indi-
vidual equipoise. In this situation it is possible that staff
will start to believe, rather than just hope, that the trial
intervention works, and this assumption might have an
impact on their recruitment practices. While this could
increase a site’s recruitment rates, it will be at the ex-
pense of research participants’ autonomy and research
standards, if staffs’ views of the trial influence the ways
that they present the trial to potential participants.
Moreover, over-optimism, or growing certainty about
the efficacy of the trial intervention, could also cause
staff to shift out of equipoise, which might result in
them refusing to recruit their patients to RCTs, because
they see this as compromising their duty of care. Such
speculations suggest there is a need for further research
that looks at the shifting relationships between evidence,
equipoise and TO.
Ethical implications
Like staff members involved in phase I trials [4], the staff
we interviewed said they had become involved in Got-it
because they had hoped the women they recruited
would derive therapeutic benefit from their participation.
Does it matter if staffs’ engagement in research is moti-
vated by a desire for therapeutic benefit rather than sci-
entific curiosity? It has been argued that the adoption of
any therapeutic orientation to research can result in a
blurring of the boundaries between clinical care and re-
search, and that this may have negative ethical implica-
tions, particularly if it results in staff confusing the goals
of research with treatment [4, 5], and conveying this to
their patients [3]. As noted above, there was no evidence
in this instance that the staffs’ TO about the use of GTN
resulted in them “mis”understanding the nature of the
activities in which they were engaged [3, 5], or that the
TO displayed in their accounts was unrealistic [6]. In-
deed, it was quite clear that staff were agreeing to recruit
to Got-it because they hoped, but did not know/believe,
that GTN might be effective in this setting. Moreover, as
noted above, the fact that there was evidence of fluctuat-
ing TO at an individual and site level suggests that TO in
this instance was firmly grounded in observed outcomes
rather than unrealistic speculations or staff misestimating
the outcomes.
Thus, following Jansen [6] and Horng and Grady [5],
we would argue that holding an optimistic view of
research is not ethically problematic per se; however, the
extent to which researchers make their optimism explicit
when recruiting trial participants is ethically important.
We suggest that it would be ethically problematic for
researchers to emphasise their hopes for a positive
outcome during recruitment, because expressions of
unsubstantiated TO, no matter how realistic, about the
efficacy and utility of trial interventions, could bias
participants’ perceptions and influence their decision-
making and hence undermine informed consent.
Practice implications
Before we look at how these findings could inform
future trial recruitment practices, it is important to note
that the impact of staffs’ observations of trial outcomes
on levels of TO and the subsequent impact on recruit-
ment may be related to the specific nature of the Got-it
trial. Arguably, the fluctuations in levels of TO that we
witnessed in Got-it, like the levels of shifting equipoise
observed by Snowdon [20], were only possible because
the design of the trial permitted on-going informal mon-
itoring. As noted above, the Got-it trial took place in an
emergency situation where staff and research partici-
pants made quick decisions, and trial outcomes were
more or less immediately apparent, enabling staff to
infer a causal link between administration of the
intervention and outcomes. In other words, unlike other
trials where recruiters may not deliver the intervention
and observe outcomes, or where the primary endpoint
may not occur for many years, in Got-it the recruiting
staff received informal feedback about individual rando-
misations practically instantaneously. This meant that
staff could get a feel for the trial findings while recruit-
ment to the pilot was on-going, despite the fact that
blinding was still in place, and adjust their levels of TO
(and individual equipoise) to accommodate these obser-
vations. Thus, we can speculate that the role played by
TO in trial recruitment may be particularly relevant in
certain types of trials, namely those in which the trial
outcomes are apparent to recruiters. Indeed, it can be
argued that some of the issues raised in this paper may
be heightened in research employing other types of trial
design, for example, randomised open label or non-
blinded trials, or complex interventions and non-CTIMP
trials, for example, those where the intervention involves
“talking” therapy versus standard care.
Given that there is an increasing number of trials
taking place in which trial outcomes are known to
recruiters during the recruitment period, our findings
point to a need for on-going staff training and support
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throughout such trials to ensure that fluctuating levels of
TO based upon staffs’ personal/lay observations do not
“contaminate” trial recruitment and delivery practices. Re-
cent research suggests that providing staff with training
about the conceptual underpinning of trial delivery —
clinical equipoise — and getting them to acknowledge
their lack of individual equipoise or trial preferences facili-
tates trial delivery by enabling them to take a more object-
ive stance towards trial recruitment and delivery [24].
Providing training throughout the lifetime of a trial that
allows staff to reflect upon how their TO about the trial is
sustained, maintained and reinforced by their trial and
other experiences might similarly be helpful and ensure
that TO does not bias recruitment rates.
Limitations
The first limitation is that this study only recruited
clinical staff who were involved in Got-it; therefore, it
does not provide insight into the views of those who had
declined to recruit to this trial. We can speculate that
had we interviewed the staff members who did not want
to become involved in Got-it, we might be presenting an
even more rich and complex picture (see, for example,
the study of Lumley et al. [22]). Second, bearing this in
mind, it can be argued that the accounts we gathered
involve a degree of self-presentation; it is possible that
the staff we interviewed tailored their accounts of trial
involvement to present themselves as responsible and
morally upstanding individuals. However, while this may
be the case, it is interesting to note that nearly everyone
we interviewed decided to present their actions as pri-
marily motivated by hope or TO. Third, these interviews
were carried out during the first few months of the Got-
it trial; one might, therefore, expect high levels of TO to
be reported at this point. A prospective or longitudinal
design involving interviews across the lifetime of a trial
could be used to explore the possibility of wider fluctua-
tions in TO and its effect on trial delivery at different
time points. Finally, this study reports data from staff
involved in one trial. As Snowdon [20] notes, staff feel
and act very differently about different trials, even ones
that take place in similar clinical settings; therefore, it is
difficult to generalise from these results. This suggests
that there is a need for further research into the influ-
ence of TO on researchers involved in different types of
trials in different clinical settings.
Conclusions
The influence of TO in clinical medicine has long been
acknowledged, but the role played by TO in clinical
research has been underspecified and under-researched
until now. This paper looks at the function of TO in
recruitment to a clinical trial. It is argued that the coex-
istence of hope and uncertainty, or TO and equipoise,
may have implications for trial recruitment by enabling
staff to sustain the level of individual equipoise needed
to ethically deliver a clinical trial. It is observed that on-
going, informal monitoring of trial outcomes may affect
recruiting staffs’ levels of TO and, as a result, staff may
require training and support so that fluctuating levels of
TO do not negatively impact trial recruitment.
Endnotes
1Although some authors argue that “hope” and
“optimism” are different concepts (Bruhn [1]), they will
be used interchangeably in this paper (cf. [2, 6, 12]).
2http://www.isrctn.com/ISRCTN88609453?q=retained
%20placenta&filters=&sort.
3In arguing that clinical equipoise is based upon
objective facts we are explicitly disregarding arguments
about the social construction of knowledge, for example,
Berger and Luckmann [25].
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